Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $284,918.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,313 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at $15,268,698. The trade was a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $84.77 on Thursday. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 21.46 and a beta of 0.43. The company has a 50-day moving average price of $81.40 and a 200-day moving average price of $79.49. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period last year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ANIP. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at approximately $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. lifted its position in ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $50,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.